- Home
- ELVN vs GHRS Comparison
ELVN vs GHRS Comparison
Compare ELVN & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELVN
- GHRS
- Stock Information
- Founded
- ELVN 2016
- GHRS 2018
- Country
- ELVN United States
- GHRS Ireland
- Employees
- ELVN N/A
- GHRS N/A
- Industry
- ELVN Biotechnology: Pharmaceutical Preparations
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- ELVN Health Care
- GHRS Health Care
- Exchange
- ELVN Nasdaq
- GHRS Nasdaq
- Market Cap
- ELVN 1.1B
- GHRS 868.7M
- IPO Year
- ELVN 2020
- GHRS 2021
- Fundamental
- Price
- ELVN $21.00
- GHRS $10.50
- Analyst Decision
- ELVN Strong Buy
- GHRS Strong Buy
- Analyst Count
- ELVN 5
- GHRS 6
- Target Price
- ELVN $37.80
- GHRS $30.67
- AVG Volume (30 Days)
- ELVN 213.5K
- GHRS 333.7K
- Earning Date
- ELVN 03-17-2025
- GHRS 05-02-2025
- Dividend Yield
- ELVN N/A
- GHRS N/A
- EPS Growth
- ELVN N/A
- GHRS N/A
- EPS
- ELVN N/A
- GHRS N/A
- Revenue
- ELVN N/A
- GHRS N/A
- Revenue This Year
- ELVN N/A
- GHRS N/A
- Revenue Next Year
- ELVN N/A
- GHRS N/A
- P/E Ratio
- ELVN N/A
- GHRS N/A
- Revenue Growth
- ELVN N/A
- GHRS N/A
- 52 Week Low
- ELVN $10.90
- GHRS $6.00
- 52 Week High
- ELVN $30.03
- GHRS $20.50
- Technical
- Relative Strength Index (RSI)
- ELVN 47.82
- GHRS 43.99
- Support Level
- ELVN $18.67
- GHRS $8.63
- Resistance Level
- ELVN $22.36
- GHRS $14.91
- Average True Range (ATR)
- ELVN 1.07
- GHRS 1.08
- MACD
- ELVN 0.06
- GHRS -0.40
- Stochastic Oscillator
- ELVN 60.84
- GHRS 31.11
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. The company is focused on developing novel and proprietary Mebufotenin 5-Methoxy-N, N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD.